title: An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA.
abstract: OBJECTIVE
  To compare 2 commercially available botulinum neuromodulators in a randomized, double-blind, split-face study.
  
  
  METHODS
  Ninety patients were treated with 10 U of onabotulinumtoxinA and 30 U of abobotulinumtoxinA for the treatment of lateral orbital rhytids. Patients were assessed live with a validated 5-point photographic scale prior to treatment and at 30 days. Patients were also photographed at each visit.
  
  
  RESULTS
  AbobotulinumtoxinA demonstrated a statistically significant advantage compared with onabotulinumtoxinA in the treatment of lateral orbital rhytids at maximal contraction, as evaluated independently by the investigator (P = .01) and patient (P = .03). AbobotulinumtoxinA was also favored by the patient over onabotulinumtoxinA 67% of the time. While abobotulinumtoxinA seemed to treat lateral orbital rhytids better at rest, as evidenced by the data and photographs, this difference was not statistically significant (P = .42).
  
  
  CONCLUSIONS
  AbobotulinumtoxinA offers superior efficacy in the treatment of lateral orbital rhytids compared with onabotulinumtoxinA. Further studies are needed to compare the 2 products in different muscle groups and for other indications.
authors.affiliation: The Maas Clinic, 2400 Clay St, San Francisco, CA 94115, USA.
authors.forename: Kartik D
authors.initials: KD
authors.lastname: Nettar
authors.forename: Kenneth C Y
authors.initials: KC
authors.lastname: Yu
authors.forename: Sumit
authors.initials: S
authors.lastname: Bapna
authors.forename: John
authors.initials: J
authors.lastname: Boscardin
authors.forename: Corey S
authors.initials: CS
authors.lastname: Maas
mesh_terms: D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D009915:Orbit; D010781:Photography; D015595:Skin Aging / Q000187:drug effects*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA